[go: up one dir, main page]

LT3303330T - 4-hidroksi-3-(heteroaril)piridin-2-ono apj agonistai, skirti panaudoti širdies ir kraujagyslių sutrikimų gydymui - Google Patents

4-hidroksi-3-(heteroaril)piridin-2-ono apj agonistai, skirti panaudoti širdies ir kraujagyslių sutrikimų gydymui

Info

Publication number
LT3303330T
LT3303330T LTEP16729454.5T LT16729454T LT3303330T LT 3303330 T LT3303330 T LT 3303330T LT 16729454 T LT16729454 T LT 16729454T LT 3303330 T LT3303330 T LT 3303330T
Authority
LT
Lithuania
Prior art keywords
heteroaril
ono
pyridin
agonists
hydroxy
Prior art date
Application number
LTEP16729454.5T
Other languages
English (en)
Lithuanian (lt)
Inventor
James A. Johnson
Soong-Hoon Kim
R. Michael Lawrence
Michael C. Myers
Hannguang J. Chao
Monique PHILLIPS
Ji Jiang
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of LT3303330T publication Critical patent/LT3303330T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D498/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
LTEP16729454.5T 2015-06-03 2016-06-02 4-hidroksi-3-(heteroaril)piridin-2-ono apj agonistai, skirti panaudoti širdies ir kraujagyslių sutrikimų gydymui LT3303330T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562170215P 2015-06-03 2015-06-03
PCT/US2016/035482 WO2016196771A1 (en) 2015-06-03 2016-06-02 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders

Publications (1)

Publication Number Publication Date
LT3303330T true LT3303330T (lt) 2019-08-12

Family

ID=56131647

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP16729454.5T LT3303330T (lt) 2015-06-03 2016-06-02 4-hidroksi-3-(heteroaril)piridin-2-ono apj agonistai, skirti panaudoti širdies ir kraujagyslių sutrikimų gydymui

Country Status (36)

Country Link
US (3) US10011594B2 (me)
EP (2) EP3530660A1 (me)
JP (2) JP6483288B2 (me)
KR (1) KR102066336B1 (me)
CN (1) CN107922401B (me)
AR (1) AR104884A1 (me)
AU (1) AU2016270903B2 (me)
CA (1) CA2988147C (me)
CL (1) CL2017003055A1 (me)
CO (1) CO2017013229A2 (me)
CY (1) CY1121938T1 (me)
DK (1) DK3303330T3 (me)
EA (1) EA034912B1 (me)
ES (1) ES2739526T3 (me)
HK (1) HK1247915B (me)
HR (1) HRP20191327T1 (me)
HU (1) HUE045546T2 (me)
IL (1) IL255951B (me)
LT (1) LT3303330T (me)
MA (1) MA41562B1 (me)
ME (1) ME03474B (me)
MX (1) MX2017014956A (me)
MY (1) MY189453A (me)
NZ (1) NZ738563A (me)
PE (1) PE20180506A1 (me)
PH (1) PH12017502158B1 (me)
PL (1) PL3303330T3 (me)
PT (1) PT3303330T (me)
RS (1) RS59220B1 (me)
SI (1) SI3303330T1 (me)
SM (1) SMT201900427T1 (me)
TN (1) TN2017000503A1 (me)
TW (1) TWI672299B (me)
UY (1) UY36705A (me)
WO (1) WO2016196771A1 (me)
ZA (1) ZA201708191B (me)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6356364B1 (ja) 2015-05-20 2018-07-11 アムジエン・インコーポレーテツド Apj受容体のトリアゾールアゴニスト
CA2988147C (en) 2015-06-03 2023-06-13 Bristol-Myers Squibb Company 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders
KR102707502B1 (ko) 2015-10-14 2024-09-13 브리스톨-마이어스 스큅 컴퍼니 Apj 효능제로서의 2,4-디히드록시-니코틴아미드
CA3007280A1 (en) 2015-12-04 2017-06-08 Bristol-Myers Squibb Company Apelin receptor agonists and methods of use
CA3008630A1 (en) * 2015-12-16 2017-06-22 Bristol-Myers Squibb Company Heteroarylhydroxypyrimidinones as agonists of the apj receptor
TWI744301B (zh) 2016-03-24 2021-11-01 美商必治妥美雅史谷比公司 做為apj促效劑之6-羥基-4-側氧-1,4-二氫嘧啶-5-甲醯胺
EP3452466B1 (en) 2016-05-03 2020-08-12 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
WO2017218617A1 (en) * 2016-06-14 2017-12-21 Bristol-Myers Squibb Company 4-hydroxy-3-sulfonylpyridin-2(1h)-ones as apj receptor agonists
WO2017218633A1 (en) 2016-06-14 2017-12-21 Bristol-Myers Squibb Company 6-hydroxy-5-(phenyl/heteroarylsulfonyl)pyrimidin-4(1h)-one as apj agonists
ES2820223T3 (es) * 2016-10-14 2021-04-20 Bristol Myers Squibb Co Agonistas de APJ de 3-sulfonil-5-aminopiridin-2,4-diol
EP3541810B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole phenyl compounds as agonists of the apj receptor
EP3541792B1 (en) 2016-11-16 2020-12-23 Amgen Inc. Triazole furan compounds as agonists of the apj receptor
US10689367B2 (en) 2016-11-16 2020-06-23 Amgen Inc. Triazole pyridyl compounds as agonists of the APJ receptor
WO2018097945A1 (en) 2016-11-16 2018-05-31 Amgen Inc. Heteroaryl-substituted triazoles as apj receptor agonists
EP3541802B1 (en) 2016-11-16 2025-01-01 Amgen Inc. Alkyl substituted triazole compounds as agonists of the apj receptor
EP3541804B1 (en) 2016-11-16 2025-01-22 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the apj receptor
US10357493B2 (en) 2017-03-10 2019-07-23 Selenity Therapeutics (Bermuda), Ltd. Metalloenzyme inhibitor compounds
US11149040B2 (en) 2017-11-03 2021-10-19 Amgen Inc. Fused triazole agonists of the APJ receptor
EP3788037A1 (en) 2018-05-01 2021-03-10 Amgen Inc. Substituted pyrimidinones as agonists of the apj receptor
CN109704980B (zh) * 2019-02-16 2022-05-13 安徽大学 一种(z)-3-氨基-2-(2-氟-3-甲氧基苯基)-2-丁烯酸乙酯的制备方法
CN109704981B (zh) * 2019-02-16 2022-01-28 安徽诺全药业有限公司 取代合成(z)-3-氨基-2-(2-氟-3-甲氧基苯基)-2-丁烯酸乙酯的方法
CN109734616B (zh) * 2019-02-16 2022-05-13 安徽诺全药业有限公司 两步法合成(z)-3-氨基-2-(2-氟-3-甲氧基苯基)-2-丁烯酸乙酯的方法
TW202438513A (zh) 2023-01-03 2024-10-01 美商百愛及生物醫藥公司 用於治療與體重增加相關之疾病或病症之愛帕琳(apelin)受體促效劑及glp-1受體促效劑之組合療法

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1001159A (en) 1910-07-25 1911-08-22 Elizabeth Nielsen Skirt-gage.
GB1472257A (en) 1973-09-10 1977-05-04 Christiaens Sa A Derivative of 4-hydroxy-5-azacoumarin
US4866182A (en) 1988-02-18 1989-09-12 Merrell Dow Pharmaceuticals Inc. Cardiotonic alkanoyl and aroyl oxazolones
US5338740A (en) 1993-07-13 1994-08-16 Pfizer Inc. Angiotensin II receptor antagonists
JP3795305B2 (ja) 1999-07-19 2006-07-12 田辺製薬株式会社 医薬組成物
ATE375340T1 (de) 2001-02-21 2007-10-15 Nps Pharma Inc Heteropolycyclische verbindungen und deren verwendung als metabotrope glutamatrezeptorantagonisten
MXPA03006597A (es) 2001-03-28 2004-10-15 Pfizer Derivados de glutaramida sustituida con n-fenpropilciclopentilo como inhibidores de nep para fsad.
US7399759B2 (en) 2001-09-03 2008-07-15 Takeda Pharmaceutical Company Limited 1, 3-benzothiazinone derivatives and use thereof
JP2005162612A (ja) 2002-01-09 2005-06-23 Ajinomoto Co Inc アシルスルホンアミド誘導体
JP2005170790A (ja) 2002-01-09 2005-06-30 Ajinomoto Co Inc N−アルキルスルフォニル置換アミド誘導体
PT1490064E (pt) * 2002-02-14 2009-12-28 Pharmacia Corp Piridinonas substituídas como moduladores de p38 map-quinase
US20040147561A1 (en) * 2002-12-27 2004-07-29 Wenge Zhong Pyrid-2-one derivatives and methods of use
WO2005004818A2 (en) 2003-07-09 2005-01-20 Imclone Systems Incorporated Heterocyclic compounds and their use as anticancer agents
US20060004001A1 (en) 2004-02-27 2006-01-05 Merz Pharma Gmbh & Co., Kgaa Tetrahydroquinolones and their use as modulators of metabotropic glutamate receptors
PE20060285A1 (es) * 2004-03-30 2006-05-08 Aventis Pharma Inc Piridonas sustituidas como inhibidores de pol(adp-ribosa)-polimerasa (parp)
MXPA06011167A (es) 2004-04-01 2007-01-25 Eli Lilli And Company Agentes del receptor h3 de histamina, preparacion y usos terapeuticos.
AU2005257999B2 (en) 2004-06-18 2011-12-08 Millennium Pharmaceuticals, Inc. Factor Xa inhibitors
DE602005014786D1 (de) 2004-07-26 2009-07-16 Lilly Co Eli Oxazolderivate als histamin-h3-rezeptor-wirkstoffe, deren herstellung und therapeutische verwendung
EP1655283A1 (en) 2004-11-08 2006-05-10 Evotec OAI AG 11beta-HSD1 Inhibitors
US20090215777A1 (en) * 2005-05-19 2009-08-27 Astex Therapeutics Ltd. Pyrimidine Derivatives As HSP90 Inhibitors
WO2007023242A1 (en) 2005-08-24 2007-03-01 Merz Pharma Gmbh & Co. Kgaa Tetrahydroquinolinones and their use as modulators of metabotropic glutamate receptors
MY161884A (en) 2006-01-23 2017-05-15 Amgen Inc Aurora kinase modulators and method of use
JP2007314516A (ja) 2006-04-25 2007-12-06 Daiichi Sankyo Co Ltd 2以上の置換基を有するベンゼン化合物を含有する医薬
AU2007281212B8 (en) 2006-08-03 2013-02-28 Trustees Of Tufts College Non-flushing niacin analogues, and methods of use thereof
WO2008019090A2 (en) 2006-08-04 2008-02-14 Praecis Pharmaceuticals Incorporated Agonists of the sphingosine-1-phosphate receptor
EP1894924A1 (en) 2006-08-29 2008-03-05 Phenex Pharmaceuticals AG Heterocyclic FXR binding compounds
MX2009005550A (es) 2006-12-01 2009-06-05 Novartis Ag Inhibidores de fosfatasa de proteina tirosina para la promocion de la hipertrofia cardiaca fisiologica.
WO2008116914A1 (en) 2007-03-28 2008-10-02 Neurosearch A/S Purinyl derivatives and their use as potassium channel modulators
CN102026970B (zh) * 2007-11-21 2013-07-31 解码遗传Ehf公司 用于治疗肺部和心血管病症的联芳基pde4抑制剂
RU2010135524A (ru) 2008-01-25 2012-02-27 Торрент Фармасьютикалз Лтд. (In) Фармацевтические комбинации
TW201000107A (en) 2008-04-09 2010-01-01 Infinity Pharmaceuticals Inc Inhibitors of fatty acid amide hydrolase
CN102047061A (zh) 2008-05-30 2011-05-04 福斯特韦勒能源股份公司 通过氧化燃料燃烧发电的方法和系统
AU2009267048A1 (en) 2008-06-30 2010-01-07 Cylene Pharmaceuticals, Inc. Oxindole compounds
EP2351743A4 (en) 2008-10-27 2012-05-09 Takeda Pharmaceutical BICYCLIC COMPOUND
WO2010053545A2 (en) * 2008-11-04 2010-05-14 Anchor Therapeutics, Inc. Apj receptor compounds
JP2013505912A (ja) 2009-09-24 2013-02-21 エフ.ホフマン−ラ ロシュ アーゲー 複素環式抗ウイルス化合物
KR20120068947A (ko) 2009-09-24 2012-06-27 에프. 호프만-라 로슈 아게 Crac 조절제로서의 인돌 유도체
WO2011062955A2 (en) 2009-11-18 2011-05-26 University Of Massachusetts Compounds for modulating tlr2
WO2011075684A1 (en) 2009-12-18 2011-06-23 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
CN102241621A (zh) 2010-05-11 2011-11-16 江苏恒瑞医药股份有限公司 5,5-双取代-2-亚氨基吡咯烷类衍生物、其制备方法及其在医药上的应用
CN102906074A (zh) 2010-05-24 2013-01-30 东亚荣养株式会社 稠合咪唑衍生物
JP5869579B2 (ja) * 2010-09-24 2016-02-24 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 置換オキサジアゾール化合物およびそれらのs1p1アゴニストとしての使用
WO2012074022A1 (ja) 2010-12-01 2012-06-07 旭硝子株式会社 イリジウムカチオン錯体および発光組成物
EP2681205B1 (en) 2011-03-03 2016-11-16 Universität des Saarlandes Biaryl derivatives as selective 17beta-hydroxysteroid dehydrogenase type 2 inhibitors
WO2012142308A1 (en) 2011-04-13 2012-10-18 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
EP2709609B1 (en) 2011-05-17 2017-10-04 Shionogi & Co., Ltd. Heterocyclic compounds
US9732051B2 (en) 2011-12-23 2017-08-15 Basf Se Isothiazoline compounds for combating invertebrate pests
WO2013164769A1 (en) * 2012-05-02 2013-11-07 Lupin Limited Substituted pyridine compounds as crac modulators
BR112014027133A2 (pt) 2012-05-09 2017-06-27 Basf Se compostos, composição agrícola ou veterinária, método para o controle das pragas de invertebrados, material de propagação dos vegetais e método para o tratamento ou proteção de um animal.
BR112014030720A8 (pt) 2012-06-08 2021-06-22 The Us Gov As Represented By The Department Of Veterans Affairs composto, composição farmacêutica e usos de inibidores de fbx03
EP2866803A1 (en) 2012-07-02 2015-05-06 Max-Delbrück-Centrum für Molekulare Medizin Berlin-Buch Psoralen derivatives for preventing or treating heart failure or cardiac hypertrophy
CN103570625A (zh) 2012-07-19 2014-02-12 南京英派药业有限公司 N-(3-杂芳基芳基)-4-芳基芳基甲酰胺和类似物作为Hedgehog通路抑制剂及其应用
WO2014031928A2 (en) 2012-08-24 2014-02-27 Philip Jones Heterocyclic modulators of hif activity for treatment of disease
PT2897939T (pt) * 2012-09-21 2017-05-04 Sanofi Sa Derivados de amida do ácido benzoimidazol-carboxílico para tratamento de doenças metabólicas ou cardiovasculares
WO2014062938A1 (en) 2012-10-19 2014-04-24 Bristol-Myers Squibb Company Rory modulators
WO2014144715A1 (en) 2013-03-15 2014-09-18 Memorial Sloan-Kettering Cancer Center Hsp90-targeted cardiac imaging and therapy
WO2015017305A1 (en) 2013-07-31 2015-02-05 Merck Sharp & Dohme Corp Inhibitors of the renal outer medullary potassium channel
JP6199197B2 (ja) 2014-02-07 2017-09-20 花王株式会社 ポリオキシアルキレンアルキルエーテルカルボン酸塩の製造方法
JP2017071553A (ja) 2014-02-25 2017-04-13 味の素株式会社 ヘテロ原子−メチレン−ヘテロ環構造を有する新規化合物
MX2016012175A (es) 2014-03-20 2017-01-19 Bayer Pharma AG Nuevos compuestos.
AU2015274781C1 (en) 2014-06-10 2019-08-08 Sanford-Burnham Medical Research Institute Metabotropic glutamate receptor negative allosteric modulators (NAMs) and uses thereof
JP6356364B1 (ja) 2015-05-20 2018-07-11 アムジエン・インコーポレーテツド Apj受容体のトリアゾールアゴニスト
CA2988147C (en) 2015-06-03 2023-06-13 Bristol-Myers Squibb Company 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders
KR101711744B1 (ko) 2015-07-16 2017-03-02 경희대학교 산학협력단 옥사디아졸 유도체, 이의 제조방법 및 이를 포함하는 전자수송층
KR102707502B1 (ko) 2015-10-14 2024-09-13 브리스톨-마이어스 스큅 컴퍼니 Apj 효능제로서의 2,4-디히드록시-니코틴아미드
WO2017091513A1 (en) 2015-11-24 2017-06-01 Daiichi Sankyo Company, Limited Novel azole derivatives as apelin receptor agonist
CA3007280A1 (en) 2015-12-04 2017-06-08 Bristol-Myers Squibb Company Apelin receptor agonists and methods of use
AU2016366310C1 (en) 2015-12-09 2021-09-09 Research Triangle Institute Improved apelin receptor (APJ) agonists and uses thereof
CA3008630A1 (en) 2015-12-16 2017-06-22 Bristol-Myers Squibb Company Heteroarylhydroxypyrimidinones as agonists of the apj receptor
TWI744301B (zh) 2016-03-24 2021-11-01 美商必治妥美雅史谷比公司 做為apj促效劑之6-羥基-4-側氧-1,4-二氫嘧啶-5-甲醯胺
WO2017218617A1 (en) 2016-06-14 2017-12-21 Bristol-Myers Squibb Company 4-hydroxy-3-sulfonylpyridin-2(1h)-ones as apj receptor agonists
WO2017218633A1 (en) 2016-06-14 2017-12-21 Bristol-Myers Squibb Company 6-hydroxy-5-(phenyl/heteroarylsulfonyl)pyrimidin-4(1h)-one as apj agonists
ES2820223T3 (es) 2016-10-14 2021-04-20 Bristol Myers Squibb Co Agonistas de APJ de 3-sulfonil-5-aminopiridin-2,4-diol

Also Published As

Publication number Publication date
PH12017502158A1 (en) 2018-06-11
CN107922401B (zh) 2021-04-16
PE20180506A1 (es) 2018-03-09
AU2016270903B2 (en) 2020-04-30
PT3303330T (pt) 2019-08-05
CA2988147A1 (en) 2016-12-08
IL255951B (en) 2021-06-30
AU2016270903A1 (en) 2018-01-18
DK3303330T3 (da) 2019-08-05
TW201708214A (zh) 2017-03-01
ME03474B (me) 2020-01-20
HUE045546T2 (hu) 2020-01-28
CA2988147C (en) 2023-06-13
CO2017013229A2 (es) 2018-03-28
JP2019094345A (ja) 2019-06-20
WO2016196771A1 (en) 2016-12-08
BR112017024846A2 (pt) 2018-08-07
EP3530660A1 (en) 2019-08-28
UY36705A (es) 2016-11-30
CN107922401A (zh) 2018-04-17
JP2018516928A (ja) 2018-06-28
KR20180014422A (ko) 2018-02-08
IL255951A (en) 2018-01-31
NZ738563A (en) 2019-09-27
KR102066336B1 (ko) 2020-01-14
SMT201900427T1 (it) 2019-09-09
CY1121938T1 (el) 2020-10-14
EA034912B1 (ru) 2020-04-06
HK1247915B (zh) 2020-04-24
TWI672299B (zh) 2019-09-21
SI3303330T1 (sl) 2019-08-30
US20160355507A1 (en) 2016-12-08
EA201792548A1 (ru) 2018-06-29
CL2017003055A1 (es) 2018-05-25
US10336739B2 (en) 2019-07-02
ES2739526T3 (es) 2020-01-31
US20180273518A1 (en) 2018-09-27
PH12017502158B1 (en) 2022-04-27
EP3303330A1 (en) 2018-04-11
PL3303330T3 (pl) 2019-10-31
RS59220B1 (sr) 2019-10-31
US10011594B2 (en) 2018-07-03
AR104884A1 (es) 2017-08-23
MY189453A (en) 2022-02-14
EP3303330B1 (en) 2019-05-01
MA41562A1 (fr) 2018-05-31
HRP20191327T1 (hr) 2019-11-01
MA41562B1 (fr) 2019-05-31
JP6483288B2 (ja) 2019-03-13
TN2017000503A1 (en) 2019-04-12
ZA201708191B (en) 2019-07-31
US20190263791A1 (en) 2019-08-29
MX2017014956A (es) 2018-04-13

Similar Documents

Publication Publication Date Title
LT3303330T (lt) 4-hidroksi-3-(heteroaril)piridin-2-ono apj agonistai, skirti panaudoti širdies ir kraujagyslių sutrikimų gydymui
IL247452A0 (en) Compounds for treatment of complement mediated disorders
LT3224269T (lt) Kompozicijos ir būdai, skirti cns sutrikimams gydyti
DK3261640T3 (da) 5ht-agonister til behandling af epilepsilidelser
DK3139925T3 (da) Valbenazin-doseringssystem til behandling af hyperkinetiske bevægelsesforstyrrelser
LT3250210T (lt) Kompozicijos ir būdai, skirti gydyti cns sutrikimus
LT3594238T (lt) Antikūno kompozicijos, skirtos navikų gydymui
LT3882250T (lt) Tetrahidropiranilamino-pirolopirimidinonas, skirtas panaudoti btk nulemtų sutrikimų gydymui
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
CL2014002710S1 (es) Dispositivo nebulizador.
DK3662925T3 (da) Sammensætning, der omfatter fsh, til behandling af infertilitet
DK3209295T3 (da) Fremgangsmåder til behandling af øjenlidelser
EP3305185A4 (en) SPHYGMOMANOMETER
DK3484475T3 (da) 1-methylnicotinamid til behandlingen af kardiovaskulær sygdom
CL2014002709S1 (es) Dispositivo nebulizador.
DK3096775T3 (da) SOCS-mimetika til behandling af sygdomme
LT3448382T (lt) Arimoklomolis, skirtas su gliukocerebrozidaze susijusiems sutrikimams gydyti
ITUA20161990A1 (it) Mangiatoia per avicoltura
DK3149163T3 (da) Prohæmostatiske proteiner til behandling af blødning
BR112016019710A2 (pt) polimorfos de (9-diclorometileno-1,2,3,4- tetraidro-1,4-metano-naftalen-5-il)-amida do ácido 3-difluorometil-1-metil-1h-pirazol-4-carboxílico
HK1250624A1 (zh) 用於治療心血管障礙的方法
DK3506956T3 (da) Lægemiddel, særlig til behandling af fistler
DK3104872T3 (da) Paricalcitol til anvendelse ved behandling af inflammatorisk
IT201700055102A1 (it) Estrattore multilinea
IT201700055981A1 (it) Dispositivo per il trattamento di malattie cardiovascolari